Amarin (AMRN) Presents REDUCE-IT Data Showing ApoB Identifies Residual Cardiovascular Risk

Amarin Corporation plc (NASDAQ: AMRN) on May 28, 2026, unveiled a new analysis from its pivotal REDUCE-IT trial, demonstrating that residual apolipoprotein B (apoB) levels effectively identify patients at elevated risk for major cardiovascular events despite statin therapy. The data showed that elevated apoB remained a strong predictor of heart attacks and strokes even when LDL cholesterol was well-controlled. This reinforces the mechanism for Vascepa (icosapent ethyl), which reduced such events by 25% in the original trial. The findings could bolster the clinical case for Vascepa in patients with high triglycerides and controlled LDL, a target market for the drug. Amarin did not provide updated sales guidance in the presentation.